Histological features of primary tumors after induction or high-dose chemotherapy in high-risk neuroblastoma

Pediatr Surg Int. 2014 Sep;30(9):919-26. doi: 10.1007/s00383-014-3564-0. Epub 2014 Jul 27.

Abstract

Purpose: In the recent years in Japan, an increasing number of patients with neuroblastoma (NB) are being treated by the "delayed local treatment (DL)" policy, undergoing surgery after the completion of high-dose chemotherapy with hematopoietic stem cell rescue (HDC). We reviewed the histopathological findings of second-look operations, including those of patients treated with DL.

Patients: From 1998 to 2013, 26 patients with high-risk NB underwent radical operation following chemotherapy. Surgery was performed after induction chemotherapy in 17 cases (standard; STD), whereas 9 cases completed induction chemotherapy and HDC before undergoing tumor resection (DL). The amount of necrosis and the degree of differentiation within the post-treatment tumor were assessed.

Results: Eighty-eight percent of the tumors showed necrosis in more than 1/3 of the specimen. Two DL cases showed complete disappearance of viable tumor cells. Amount of necrosis did not affect the prognosis of the patient. Tumors with immature, poorly differentiated phenotypes showed an extremely aggressive thereafter. Though not statistically proven, (123)I-MIBG (metaiodobenzylguanidine) uptake may be correlated with the amount of viable cells remaining within the tumor, but not with the degree of differentiation.

Conclusions: Our results support the previous reports advocating that tumors that sustain unfavorable histology after chemotherapy behave aggressively thereafter.

MeSH terms

  • 3-Iodobenzylguanidine
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Humans
  • Induction Chemotherapy / methods*
  • Infant
  • Japan
  • Male
  • Neuroblastoma / diagnostic imaging*
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / surgery
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Retrospective Studies
  • Second-Look Surgery / methods
  • Survival Analysis
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • 3-Iodobenzylguanidine